I was taking notes. Not like i was making but it turned out at the hand of our interview retired for several hours and when i got to build a given my credit card to pick up the tab, he said you really dont look anything like i expected. I thought you were paul. I immediately knew what it happened. There is another Ken Silverstein in West Virginia who writes a lot about the oil industry. He writes her trade industry publication and is very, very i would say more sympathetic to the industry and circumspect than i am. So i felt obliged to say i think theres been a misunderstanding. But because of that misunderstanding, i did hear a lot of very interesting stories. And to her great credit, even afterwards she clearly was surprised when i said i am not that Ken Silverstein. As she continued to talk to me all along although it was originally the chapter is based on the piece for harpers magazine and has spoken with are much than then. Host so you close within. Why . Guest truly because its a
Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability Shareholder commitment to TauRxrepresents a significant success story for UK-based life sciences research and development in areas of great unmet medical need TauRxwill present the Phase 3 findings at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco ABERDEEN, Scotland and SINGAPORE, Nov. 14, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer's disease (AD). Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. It is a hallmark of the disease recognised as an important potential target for treating AD. HMTM is an oral tau aggregation inhibitor, targeting this underlying pathology. Glen
Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability Shareholder commitment to TauRxrepresents a significant success story for UK-based life sciences research and development in areas of great unmet medical need TauRxwill present the Phase 3 findings at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco ABERDEEN, Scotland and SINGAPORE, Nov. 14, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in tau-based research in Alzheimer's disease (AD). Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. It is a hallmark of the disease recognised as an important potential target for treating AD. HMTM is an oral tau aggregation inhibitor, targeting this underlying pathology. Glen
Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting.